GMAB News and Press, Genmab A/S From 01/29/21

Genmab A/S ([[GMAB]] -1.5%) gets positive recommendation for marketing approval for its subcutaneous ofatumumab for the treatment of relapsing forms of multiple sclerosis in certain adults from the Committee for Medicinal Products for Human Use ((CHMP)).Ofatumumab is being developed and ...

Genmab A/S (GMAB) has announced that the FDA has approved DARZALEX FASPRO® to treat newly diagnosed Light-chain (“AL”) amyloidosis, a rare disease affecting an estimated ~3,000 to 4,000 individuals in the U.S. annually.Janssen Biotech, Inc. (Janssen) of Johnson & Johnso...

Genmab ([[GMAB]]) reached the first milestone in its collaboration with AbbVie with a $40M milestone payment triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator's choice of chemotherapy in patients with relapsed or refractory diffuse ...

Cullinan Management (CGEM) has priced upsized initial public offering of 11.9M common shares at $21/share, for expected gross proceeds of ~$249.9M.The company previously planned to raise $195M by offering 10M shares at a price range of $19 to $20 above the original offering of 8.3M shares at ...

Genmab ([[GMAB]] -0.4%) announces initiation of innovaTV 301 Phase 3 trial evaluating tisotumab vedotin in patients with recurrent or metastatic cervical cancer who have received one or two prior lines of systemic therapy. The 482-subject study will evaluate efficacy of tisotumab compare...

Genmab is a well-managed and vast European biopharma R&D giant. Its partnered products and self-owned pipelines are vast. This is a stock to accumulate at dips. For further details see: Genmab: An European R&D Behemoth With Long-Term Potential

Halvorsen's 13F portfolio value increased from $23.14B to $27.68B. The number of positions increased 71 to 86. Viking Global increased Microsoft, Mecadolibre, and CME Group while reducing Amazon.com and dropping Uber Technologies & JD.com. The top three positions are Microsoft...

Genmab ([[GMAB]] -2.1%) after news that  it's discontinuing its Phase 2 study of enapotamab vedotin and dropping development as the data from the expansion cohorts did not meet Genmab’s stringent criteria for proof-of-concept.“We are committed to developing i...

ImmunoPrecise (IPATF) has entered into a research agreement with Genmab (GMAB), wherein IPA will generate bispecific antibody combinations using Genmab's proprietary DuoBody platform and IPA's proprietary antibodies in the field of infectious disease.As a part of the partnership, Ge...

BioMarin is a leader in rare disease therapy discovery with multiple competitive advantages including scale, expertise, patents and relationships. Two major catalysts for 2021 provide investors with favorable risk/reward skew afforded by a low share price that should not be ignored. ...